Press Release

Change of Directors and Organizational Change

TOKYO, April 27, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that at a meeting of its Board of Directors held today, it decided a change in Directors as stated below. This change is subject to approval at the 15th Term Annual Shareholders Meeting and a decision at the Board of Directors meeting, both scheduled on June 18, 2020. To strengthen support for auditing by the Audit & Supervisory Committee, the Audit & Supervisory Committee Office was established as of April, 2020, with increased number of full-time staff. The staff of the Audit & Supervisory Committee Office are independent from the Directors who are not the Committee Members and carry out their duties under the direct control of the Audit & Supervisory Committee.

1. Candidates for Directors (excluding Directors who are Audit & Supervisory Committee Members)

Name		Current Position
Yoshihiko Hatanaka	Reelection	Representative Director, Chairman of the Board
Kenji Yasukawa	Reelection	Representative Director, President and CEO
Naoki Okamura	Reelection	Representative Director, Corporate Executive Vice President, Chief Strategy Officer (CStO) and Chief Financial Officer (CFO)
Mamoru Sekiyama	Outside Reelection	Outside Director and Audit & Supervisory Committee Member, A.D. Works Group Co., Ltd.
Keiko Yamagami	Outside Reelection	Lawyer honorary member, Tokyo Seiwa Law Office Outside Audit & Supervisory Board Member, Denyo Co., Ltd.
Hiroshi Kawabe	Outside Reelection	Professor Emeritus, Keio University President, Foundation for Promotion of Medical Training
Tatsuro Ishizuka	Outside Reelection	Advisor, Hitachi, Ltd. Outside director, K&O Energy Group Inc.

The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act.

2. Candidates for Directors who are Audit & Supervisory Committee Members

Name		Current Position
Toru Yoshimitsu	New Candidate	Report to CEO
Hiroo Sasaki	Outside Reelection	Professor, Graduate School of Accountancy, Waseda University
Raita Takahashi	Outside New Candidate	Representative, TAKAHASHI Accounting & Tax office Outside Audit & Supervisory Board Member, Alpha Group Inc. Representative Director, Yoshida Management Co. Ltd.

The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act. Mr. Raita Takahashi was elected as a substitute Director who is an Audit & Supervisory Committee Member at the 14th Term Annual Shareholders Meeting on June 18, 2019, but will resign from the substitute Director who is an Audit & Supervisory Committee Member at the start of the 15th Term Annual Shareholders Meeting.

3. Directors to be retired

Director, Audit & Supervisory Committee Member	Tomokazu Fujisawa
Director, Audit & Supervisory Committee Member	Hiroko Sakai
Outside Director, Audit & Supervisory Committee Member	Noriyuki Uematsu

4. The Board of Directors as from June 18, 2020 (planned)

Yoshihiko Hatanaka (Representative Director, Chairman of the Board)

Kenji Yasukawa (Representative Director, President and CEO)

Naoki Okamura (Representative Director, Executive Vice President)

Mamoru Sekiyama (Outside Director)

Keiko Yamagami (Outside Director)

Hiroshi Kawabe (Outside Director)

Tatsuro Ishizuka (Outside Director)

Toru Yoshimitsu (Director, Audit & Supervisory Committee Member)

Hiroo Sasaki (Outside Director, Audit & Supervisory Committee Member)

Haruko Shibumura (Outside Director, Audit & Supervisory Committee Member)

Raita Takahashi (Outside Director, Audit & Supervisory Committee Member)

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at https://www.astellas.com/en

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Advocacy & Relations
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473